CohBar's Acquisition Partner Touts Encouraging Data From Personalized Cancer Vaccine
Portfolio Pulse from Vandana Singh
CohBar Inc (NASDAQ:CWBR) and Morphogenesis Inc announced positive initial results from an exploratory analysis of their personalized cancer vaccine candidate, IFx-Hu2.0, for Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC) patients. The ongoing Phase 1b study showed 71% of patients experienced objective anti-tumor responses to ICI rechallenge.
June 05, 2023 | 4:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CohBar Inc (NASDAQ:CWBR) and Morphogenesis Inc announced positive initial results from their personalized cancer vaccine candidate, IFx-Hu2.0, in an ongoing Phase 1b study.
The positive initial results from the exploratory analysis of IFx-Hu2.0 indicate that the personalized cancer vaccine candidate is showing promise in overcoming primary resistance to checkpoint inhibitors. This could potentially lead to increased interest in CohBar's stock and a positive short-term impact on its price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100